-
Something wrong with this record ?
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
RJ. Motzer, BI. Rini, DF. McDermott, O. Arén Frontera, HJ. Hammers, MA. Carducci, P. Salman, B. Escudier, B. Beuselinck, A. Amin, C. Porta, S. George, V. Neiman, S. Bracarda, SS. Tykodi, P. Barthélémy, R. Leibowitz-Amit, ER. Plimack, SF. Oosting,...
Language English Country Great Britain
Document type Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Grant support
P30 CA008748
NCI NIH HHS - United States
NLK
ProQuest Central
from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest)
from 2000-09-01 to 2 months ago
Public Health Database (ProQuest)
from 2000-09-01 to 2 months ago
- MeSH
- Alanine Transaminase blood MeSH
- Amylases blood MeSH
- Intention to Treat Analysis MeSH
- Progression-Free Survival MeSH
- Hypertension chemically induced MeSH
- Ipilimumab administration & dosage MeSH
- Carcinoma, Renal Cell drug therapy MeSH
- Humans MeSH
- Lipase blood MeSH
- Survival Rate MeSH
- Kidney Neoplasms drug therapy MeSH
- Follow-Up Studies MeSH
- Nivolumab administration & dosage MeSH
- Paresthesia chemically induced MeSH
- Antineoplastic Agents adverse effects therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects therapeutic use MeSH
- Sunitinib adverse effects therapeutic use MeSH
- Fatigue chemically induced MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Research Support, N.I.H., Extramural MeSH
- Comparative Study MeSH
BACKGROUND: In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile. In this study, we aimed to assess efficacy and safety after extended follow-up to inform the long-term clinical benefit of nivolumab plus ipilimumab versus sunitinib in this setting. METHODS: In the phase 3, randomised, controlled CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced, or metastatic histologically confirmed renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries. Patients were categorised by International Metastatic Renal Cell Carcinoma Database Consortium risk status into favourable-risk, intermediate-risk, and poor-risk subgroups and randomly assigned (1:1) to open-label nivolumab (3 mg/kg intravenously) plus ipilimumab (1 mg/kg intravenously) every 3 weeks for four doses, followed by nivolumab (3 mg/kg intravenously) every 2 weeks; or sunitinib (50 mg orally) once daily for 4 weeks (6-week cycle). Randomisation was done through an interactive voice response system, with a block size of four and stratified by risk status and geographical region. The co-primary endpoints for the trial were overall survival, progression-free survival per independent radiology review committee (IRRC), and objective responses per IRRC in intermediate-risk or poor-risk patients. Secondary endpoints were overall survival, progression-free survival per IRRC, and objective responses per IRRC in the intention-to-treat population, and adverse events in all treated patients. In this Article, we report overall survival, investigator-assessed progression-free survival, investigator-assessed objective response, characterisation of response, and safety after extended follow-up. Efficacy outcomes were assessed in all randomly assigned patients; safety was assessed in all treated patients. This study is registered with ClinicalTrials.gov, number NCT02231749, and is ongoing but now closed to recruitment. FINDINGS: Between Oct 16, 2014, and Feb 23, 2016, of 1390 patients screened, 1096 (79%) eligible patients were randomly assigned to nivolumab plus ipilimumab or sunitinib (550 vs 546 in the intention-to-treat population; 425 vs 422 intermediate-risk or poor-risk patients, and 125 vs 124 favourable-risk patients). With extended follow-up (median follow-up 32·4 months [IQR 13·4-36·3]), in intermediate-risk or poor-risk patients, results for the three co-primary efficacy endpoints showed that nivolumab plus ipilimumab continued to be superior to sunitinib in terms of overall survival (median not reached [95% CI 35·6-not estimable] vs 26·6 months [22·1-33·4]; hazard ratio [HR] 0·66 [95% CI 0·54-0·80], p<0·0001), progression-free survival (median 8·2 months [95% CI 6·9-10·0] vs 8·3 months [7·0-8·8]; HR 0·77 [95% CI 0·65-0·90], p=0·0014), and the proportion of patients achieving an objective response (178 [42%] of 425 vs 124 [29%] of 422; p=0·0001). Similarly, in intention-to-treat patients, nivolumab and ipilimumab showed improved efficacy compared with sunitinib in terms of overall survival (median not reached [95% CI not estimable] vs 37·9 months [32·2-not estimable]; HR 0·71 [95% CI 0·59-0·86], p=0·0003), progression-free survival (median 9·7 months [95% CI 8·1-11·1] vs 9·7 months [8·3-11·1]; HR 0·85 [95% CI 0·73-0·98], p=0·027), and the proportion of patients achieving an objective response (227 [41%] of 550 vs 186 [34%] of 546 p=0·015). In all treated patients, the most common grade 3-4 treatment-related adverse events in the nivolumab and ipilimumab group were increased lipase (57 [10%] of 547), increased amylase (31 [6%]), and increased alanine aminotransferase (28 [5%]), whereas in the sunitinib group they were hypertension (90 [17%] of 535), fatigue (51 [10%]), and palmar-plantar erythrodysaesthesia (49 [9%]). Eight deaths in the nivolumab plus ipilimumab group and four deaths in the sunitinib group were reported as treatment-related. INTERPRETATION: The results suggest that the superior efficacy of nivolumab plus ipilimumab over sunitinib was maintained in intermediate-risk or poor-risk and intention-to-treat patients with extended follow-up, and show the long-term benefits of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma across all risk categories. FUNDING: Bristol-Myers Squibb and ONO Pharmaceutical.
Bristol Myers Squibb Princeton NJ USA
Department of Cancer Services Oncology Mount Vernon Cancer Centre Northwood Middlesex UK
Department of Hematology and Oncology Fox Chase Cancer Center Philadelphia PA USA
Department of Medical Oncology Centro de Invetigación Clínica Bradford Hill Santiago Chile
Department of Medical Oncology Fundación Arturo López Pérez Santiago Chile
Department of Medical Oncology Gustave Roussy Villejuif France
Department of Medical Oncology Hôpitaux Universitaires de Strasbourg Strasbourg France
Department of Medical Oncology Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain
Department of Medical Oncology IRCCS San Matteo University Hospital Foundation Pavia Italy
Department of Medical Oncology Westmead Hospital and Macquarie University Sydney NSW Australia
Department of Medicine British Columbia Cancer Agency Vancouver BC Canada
Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA
Department of Medicine Roswell Park Cancer Institute Buffalo NY USA
Department of Oncology Aarhus University Hospital Aarhus Denmark
Department of Oncology Davidoff Cancer Center Rabin Medical Center Petah Tikva Israel
Department of Oncology Monash Health Melbourne VIC Australia
Department of Oncology Palacky University and University Hospital Olomouc Olomouc Czech Republic
Department of Oncology Tom Baker Cancer Center University of Calgary Calgary AB Canada
Department of Oncology University Hospitals Leuven Leuven Belgium
Department of Urology Jena University Hospital Jena Germany
Department of Urology Niigata University Niigata Japan
Division of Medical Oncology Duke Cancer Institute Durham NC USA
Harvard Medical School Boston MA USA
Levine Cancer Institute Atrium Healthcare Charlotte NC USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023644
- 003
- CZ-PrNML
- 005
- 20201214130711.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(19)30413-9 $2 doi
- 035 __
- $a (PubMed)31427204
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Motzer, Robert J $u Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org.
- 245 10
- $a Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial / $c RJ. Motzer, BI. Rini, DF. McDermott, O. Arén Frontera, HJ. Hammers, MA. Carducci, P. Salman, B. Escudier, B. Beuselinck, A. Amin, C. Porta, S. George, V. Neiman, S. Bracarda, SS. Tykodi, P. Barthélémy, R. Leibowitz-Amit, ER. Plimack, SF. Oosting, B. Redman, B. Melichar, T. Powles, P. Nathan, S. Oudard, D. Pook, TK. Choueiri, F. Donskov, MO. Grimm, H. Gurney, DYC. Heng, CK. Kollmannsberger, MR. Harrison, Y. Tomita, I. Duran, V. Grünwald, MB. McHenry, S. Mekan, NM. Tannir, CheckMate 214 investigators,
- 520 9_
- $a BACKGROUND: In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile. In this study, we aimed to assess efficacy and safety after extended follow-up to inform the long-term clinical benefit of nivolumab plus ipilimumab versus sunitinib in this setting. METHODS: In the phase 3, randomised, controlled CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced, or metastatic histologically confirmed renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries. Patients were categorised by International Metastatic Renal Cell Carcinoma Database Consortium risk status into favourable-risk, intermediate-risk, and poor-risk subgroups and randomly assigned (1:1) to open-label nivolumab (3 mg/kg intravenously) plus ipilimumab (1 mg/kg intravenously) every 3 weeks for four doses, followed by nivolumab (3 mg/kg intravenously) every 2 weeks; or sunitinib (50 mg orally) once daily for 4 weeks (6-week cycle). Randomisation was done through an interactive voice response system, with a block size of four and stratified by risk status and geographical region. The co-primary endpoints for the trial were overall survival, progression-free survival per independent radiology review committee (IRRC), and objective responses per IRRC in intermediate-risk or poor-risk patients. Secondary endpoints were overall survival, progression-free survival per IRRC, and objective responses per IRRC in the intention-to-treat population, and adverse events in all treated patients. In this Article, we report overall survival, investigator-assessed progression-free survival, investigator-assessed objective response, characterisation of response, and safety after extended follow-up. Efficacy outcomes were assessed in all randomly assigned patients; safety was assessed in all treated patients. This study is registered with ClinicalTrials.gov, number NCT02231749, and is ongoing but now closed to recruitment. FINDINGS: Between Oct 16, 2014, and Feb 23, 2016, of 1390 patients screened, 1096 (79%) eligible patients were randomly assigned to nivolumab plus ipilimumab or sunitinib (550 vs 546 in the intention-to-treat population; 425 vs 422 intermediate-risk or poor-risk patients, and 125 vs 124 favourable-risk patients). With extended follow-up (median follow-up 32·4 months [IQR 13·4-36·3]), in intermediate-risk or poor-risk patients, results for the three co-primary efficacy endpoints showed that nivolumab plus ipilimumab continued to be superior to sunitinib in terms of overall survival (median not reached [95% CI 35·6-not estimable] vs 26·6 months [22·1-33·4]; hazard ratio [HR] 0·66 [95% CI 0·54-0·80], p<0·0001), progression-free survival (median 8·2 months [95% CI 6·9-10·0] vs 8·3 months [7·0-8·8]; HR 0·77 [95% CI 0·65-0·90], p=0·0014), and the proportion of patients achieving an objective response (178 [42%] of 425 vs 124 [29%] of 422; p=0·0001). Similarly, in intention-to-treat patients, nivolumab and ipilimumab showed improved efficacy compared with sunitinib in terms of overall survival (median not reached [95% CI not estimable] vs 37·9 months [32·2-not estimable]; HR 0·71 [95% CI 0·59-0·86], p=0·0003), progression-free survival (median 9·7 months [95% CI 8·1-11·1] vs 9·7 months [8·3-11·1]; HR 0·85 [95% CI 0·73-0·98], p=0·027), and the proportion of patients achieving an objective response (227 [41%] of 550 vs 186 [34%] of 546 p=0·015). In all treated patients, the most common grade 3-4 treatment-related adverse events in the nivolumab and ipilimumab group were increased lipase (57 [10%] of 547), increased amylase (31 [6%]), and increased alanine aminotransferase (28 [5%]), whereas in the sunitinib group they were hypertension (90 [17%] of 535), fatigue (51 [10%]), and palmar-plantar erythrodysaesthesia (49 [9%]). Eight deaths in the nivolumab plus ipilimumab group and four deaths in the sunitinib group were reported as treatment-related. INTERPRETATION: The results suggest that the superior efficacy of nivolumab plus ipilimumab over sunitinib was maintained in intermediate-risk or poor-risk and intention-to-treat patients with extended follow-up, and show the long-term benefits of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma across all risk categories. FUNDING: Bristol-Myers Squibb and ONO Pharmaceutical.
- 650 _2
- $a alanintransaminasa $x krev $7 D000410
- 650 _2
- $a amylasy $x krev $7 D000681
- 650 _2
- $a protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D000970
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
- 650 _2
- $a karcinom z renálních buněk $x farmakoterapie $7 D002292
- 650 _2
- $a únava $x chemicky indukované $7 D005221
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypertenze $x chemicky indukované $7 D006973
- 650 _2
- $a analýza podle původního léčebného záměru $7 D057194
- 650 _2
- $a ipilimumab $x aplikace a dávkování $7 D000074324
- 650 _2
- $a nádory ledvin $x farmakoterapie $7 D007680
- 650 _2
- $a lipasa $x krev $7 D008049
- 650 _2
- $a nivolumab $x aplikace a dávkování $7 D000077594
- 650 _2
- $a parestezie $x chemicky indukované $7 D010292
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a sunitinib $x škodlivé účinky $x terapeutické užití $7 D000077210
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rini, Brian I $u Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
- 700 1_
- $a McDermott, David F $u Department of Hematology and Medical Oncology, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
- 700 1_
- $a Arén Frontera, Osvaldo $u Department of Medical Oncology, Centro de Invetigación Clínica Bradford Hill, Santiago, Chile.
- 700 1_
- $a Hammers, Hans J $u Department of Oncology and Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
- 700 1_
- $a Carducci, Michael A $u Department of Oncology and Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
- 700 1_
- $a Salman, Pamela $u Department of Medical Oncology, Fundación Arturo López Pérez, Santiago, Chile.
- 700 1_
- $a Escudier, Bernard $u Department of Medical Oncology, Gustave Roussy, Villejuif, France.
- 700 1_
- $a Beuselinck, Benoit $u Department of Oncology, University Hospitals Leuven, Leuven, Belgium.
- 700 1_
- $a Amin, Asim $u Levine Cancer Institute, Atrium Healthcare, Charlotte, NC, USA.
- 700 1_
- $a Porta, Camillo $u Department of Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy.
- 700 1_
- $a George, Saby $u Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
- 700 1_
- $a Neiman, Victoria $u Department of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; Tel Aviv University, Tel Aviv, Israel.
- 700 1_
- $a Bracarda, Sergio $u Department of Oncology, Ospedale San Donato, Azienda USL Toscana Sud-Est, IstitutoToscanoTumori, Arezzo, Italy.
- 700 1_
- $a Tykodi, Scott S $u Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- 700 1_
- $a Barthélémy, Philippe $u Department of Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
- 700 1_
- $a Leibowitz-Amit, Raya $u Oncology Department, Sheba Medical Center, Ramat Gan, Israel.
- 700 1_
- $a Plimack, Elizabeth R $u Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
- 700 1_
- $a Oosting, Sjoukje F $u Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- 700 1_
- $a Redman, Bruce $u Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
- 700 1_
- $a Melichar, Bohuslav $u Department of Oncology, Palacky University, and University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Powles, Thomas $u Department of Genitourinary Oncology, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust, London, UK.
- 700 1_
- $a Nathan, Paul $u Department of Cancer Services: Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
- 700 1_
- $a Oudard, Stéphane $u Department of Medical Oncology, Service de Cancérologie Médicale Hôpital Européen Georges Pompidou, Paris, France.
- 700 1_
- $a Pook, David $u Department of Oncology, Monash Health, Melbourne, VIC, Australia.
- 700 1_
- $a Choueiri, Toni K $u Department of Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
- 700 1_
- $a Donskov, Frede $u Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
- 700 1_
- $a Grimm, Marc-Oliver $u Department of Urology, Jena University Hospital, Jena, Germany.
- 700 1_
- $a Gurney, Howard $u Department of Medical Oncology, Westmead Hospital and Macquarie University, Sydney, NSW, Australia.
- 700 1_
- $a Heng, Daniel Y C $u Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.
- 700 1_
- $a Kollmannsberger, Christian K $u Department of Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada.
- 700 1_
- $a Harrison, Michael R $u Division of Medical Oncology, Duke Cancer Institute, Durham, NC, USA.
- 700 1_
- $a Tomita, Yoshihiko $u Department of Urology, Niigata University, Niigata, Japan.
- 700 1_
- $a Duran, Ignacio $u Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain.
- 700 1_
- $a Grünwald, Viktor $u Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, University Hospital Essen, Essen, Germany.
- 700 1_
- $a McHenry, M Brent $u Bristol-Myers Squibb, Princeton, NJ, USA.
- 700 1_
- $a Mekan, Sabeen $u Bristol-Myers Squibb, Princeton, NJ, USA.
- 700 1_
- $a Tannir, Nizar M $u Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
- 710 2_
- $a CheckMate 214 investigators
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 20, č. 10 (2019), s. 1370-1385
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31427204 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214130708 $b ABA008
- 999 __
- $a ok $b bmc $g 1595963 $s 1114320
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 20 $c 10 $d 1370-1385 $e 20190816 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- GRA __
- $a P30 CA008748 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20201125
